Related Experiment Video
Updated: Jul 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Aspirin in the treatment and prevention of cardiovascular disease
J M Gaziano1, P J Skerrett, J E Buring
1Division of Preventive Medicine, Cardiovascular Division, and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02215, USA. graziano@maveric.org
Insights
Aspirin significantly reduces cardiovascular risks for heart attack patients and those with existing cardiovascular disease. However, its effectiveness in primary prevention requires more research, especially in women.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Aspirin is widely studied for cardiovascular disease prevention.
- Trials have focused on acute myocardial infarction (MI), prior cardiovascular disease, and primary prevention.
Purpose of the Study:
- To summarize the evidence for aspirin's efficacy in different patient populations.
- To highlight gaps in current research, particularly for primary prevention.
Main Methods:
- Review of randomized trials involving aspirin in various cardiovascular contexts.
- Analysis of outcomes including nonfatal MI, nonfatal stroke, and cardiovascular death.
Main Results:
- Aspirin initiation within 24 hours of acute MI reduces cardiovascular events and death.
- In patients with existing cardiovascular disease, aspirin lowers risks of MI, stroke, and vascular death.
- Primary prevention trials show aspirin reduces first MI risk in men, but data for stroke and total death are limited; data in women are lacking.
Conclusions:
- Aspirin is a proven intervention for secondary cardiovascular prevention and acute MI management.
- The role of aspirin in primary prevention requires further investigation, especially in diverse populations.
- Clinical decisions regarding primary prevention should consider physician judgment and management of other risk factors.
Abstract:
Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects. Initiating aspirin therapy within 24 h after the onset of symptoms of an acute MI results in conclusive reductions in the risk of nonfatal reinfarction, nonfatal stroke and total cardiovascular death. In a wide range of patients with prior occlusive cardiovascular disease, aspirin reduces the risks of nonfatal MI, nonfatal stroke and vascular death. In primary prevention trials, aspirin has been shown to reduce the risk of a first MI in men; limited data make it difficult to draw conclusions regarding its effect on stroke and total cardiovascular death. Randomized data from studies in women and other populations are lacking. Until more data are available, the decision to use aspirin in primary prevention should be based on the clinical judgment of the physician and it should be used as an adjunct in the management of other cardiovascular disease risk factors.
More Related Videos
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

